Candel Therapeutics (CADL) Cash from Operations (2020 - 2025)

Candel Therapeutics has disclosed Cash from Operations across 6 years of filings, most recently posting 10568000.0 for Q4 2025.

• Cash from Operations for Q4 2025 came in at 10568000.0, down 81.77% year-over-year; the trailing twelve-month figure through Dec 2025 was 38311000.0 (down 41.77% YoY), and the FY2025 annual result was 38311000.0, down 41.77% from the prior year.
• Cash from Operations came in at 10568000.0 for Q4 2025 at Candel Therapeutics, down from 10236000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 4459000.0 in Q2 2021 to a low of 10819000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 7308500.0 (2023), against an average of 7660750.0.
• Across the five-year window, Cash from Operations plunged 358.07% in 2021 and rose 25.37% in 2024, its largest moves.
• Candel Therapeutics' Cash from Operations stood at 5238000.0 in 2021, then slumped by 31.44% to 6885000.0 in 2022, then retreated by 7.8% to 7422000.0 in 2023, then grew by 21.67% to 5814000.0 in 2024, then plunged by 81.77% to 10568000.0 in 2025.
• The last three Cash from Operations figures came in at 10568000.0 (Q4 2025), 10236000.0 (Q3 2025), and 8891000.0 (Q2 2025), per Business Quant data.